Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.

Blood cancer journal

PubMedID: 26871714

Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 2016;6e396.
The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma. Fourteen patients were enrolled in the study, eleven of whom qualified to receive therapy. A majority of patients (81. 8%) completed the minimal number or more of the four required cycles, while two patients completed only three cycles. The maximum tolerated dose (MTD) of siltuximab with RVD was dose level -1 (siltuximab: 8. 3?mg/kg; bortezomib: 1. 3?mg/m(2); lenalidomide: 25?mg; dexamethasone: 20?mg). Serious adverse events were grade 3 pneumonia and grade 4 thrombocytopenia, and no deaths occurred during the study or with follow-up (median follow-up 28. 1 months). An overall response rate, after 3-4 cycles of therapy, of 90. 9% (95% confidence interval (CI): 58. 7%, 99. 8%) (9. 1% complete response (95% CI: 0. 2%, 41. 3%), 45. 5% very good partial response (95% CI: 16. 7%, 76. 6%) and 36. 4% partial response (95% CI: 10. 9%, 69. 2%)) was seen. Two patients withdrew consent, and nine patients (81. 8%) opted for autologous stem cell transplantation.